SS-31 (Elamipretide): Mitochondrial Research in Aging Models

SS-31 (Elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto at Cornell University Medical College that selectively concentrates in the inner mitochondrial membrane (IMM), targeting cardiolipin — a phospholipid unique to the IMM critical for electron transport chain (ETC) function.

Cardiolipin: The Molecular Target

Cardiolipin stabilises ETC complexes in supercomplexes, interacts directly with cytochrome c to maintain electron carrier efficiency, and provides the IMM structural scaffold. With aging and disease, cardiolipin undergoes peroxidation by ROS generated at ETC Complexes I and III. Oxidised cardiolipin dissociates from cytochrome c, disrupting electron flow and amplifying ROS production in a self-sustaining cycle.

SS-31 binds directly to cardiolipin, preventing its peroxidation and stabilising the cardiolipin-cytochrome c interaction — restoring ETC supercomplex stability and breaking the ROS amplification cycle.

The Aging Kidney: Bioenergetic Restoration

Birk AV et al. (*Journal of the American Society of Nephrology*, 2013) applied SS-31 to aged rat kidneys (22-month-old Sprague-Dawley rats):

• ATP production rate: increased 2.1-fold vs untreated aged kidneys
• Mitochondrial membrane potential: normalised to levels comparable to 4-month-old controls
• ROS production: decreased 67% vs aged controls
• Cristae density: significantly improved by electron microscopy

The near-complete bioenergetic restoration in tissue with decades of cumulative mitochondrial damage was described by the authors as striking and unexpected.

Cardiac Ischaemia-Reperfusion

In rat MI models, SS-31 dramatically reduces infarct size:

• Infarct size at 2h reperfusion: 65% reduction vs vehicle (Cho J et al., *Antioxidants & Redox Signaling*, 2007)
• Mitochondrial permeability transition pore opening: delayed 2-3× vs controls
• Cardiomyocyte survival at border zone: ~40% higher vs controls

Elamipretide (the clinical name for SS-31) has been evaluated in Phase 2/3 trials for heart failure with reduced ejection fraction (HFREF) and Barth syndrome, a genetic cardiolipin synthesis disorder.

Skeletal Muscle Aging

Siegel MP et al. (*Aging Cell*, 2013) — 8 weeks of daily SS-31 in 26-month-old mice:

• Peak treadmill capacity: improved 28%
• Subsarcolemmal mitochondrial ROS: reduced 42%
• PGC-1α and TFAM expression: partially restored toward young-adult levels

How SS-31 Compares to [Epithalon](/peptides/epithalon)

While Epithalon addresses telomere attrition (a replicative aging mechanism), SS-31 addresses mitochondrial dysfunction — a distinct hallmark of aging. The two are mechanistically complementary rather than redundant.

SS-31/Elamipretide is in active clinical development for heart failure and Barth syndrome. Research compound for other applications.

<!-- deep-links-v1 -->

Related Neuroendocrine and Aging Peptides

SS-31's mitochondrial cardiolipin targeting connects to broader peptide aging research. Orexin-A and Orexin-B regulate hypothalamic energy sensing, a process critically dependent on mitochondrial function in orexin neurons. Vasopressin (AVP) is a neuropeptide that modulates renal water retention and central cognitive function — both processes where mitochondrial efficiency is relevant. DSIP (Delta Sleep-Inducing Peptide) has anti-oxidative and stress-modulating properties in aging brain models that complement SS-31's mitochondrial ROS reduction. TRH (Thyrotropin-Releasing Hormone) interacts with thyroid hormone signaling, which directly governs mitochondrial biogenesis and uncoupling. Beta-Endorphin influences mitochondrial membrane potential in stressed cells through mu-opioid receptor coupling. Neurotensin, Galanin, and Nociceptin/Orphanin FQ represent the neuropeptide dimension of the aging CNS research landscape where mitochondrial protection is a common mechanism of interest.